Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health…
By Jack Cuzick, Mitchell Dowsett, S. Pineda, C. Wale, J. Salter, E. Quinn, L. Zabaglo, E. Mallon, A. Green, Ian O. Ellis and 3 more. Journal of Clinical Oncology, 2011
724 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics
View Paper: https://www.semanticscholar.org/paper/7d5fd5ad1994488d18fe233c9efdfedacb3781de
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Charles M. Perou
- Lisa A. Carey
- Mitchell Dowsett
- S. Leung
- Torsten O. Nielsen
- H. Horlings
- Balázs Győrffy
In Genetics
Citations in the corpus
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “tested and validated in a single institutional research laboratory that minimized preanalytic, analytic, and postanalytic variables.(36,41) Although the published data are strong, the test has not been shown to be sufficiently reproducible in other academic or clinical laboratories to recommend it f”
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, result): “say, designated IHC4, might be more generally accessible and provide similar results at a lower cost (66) if these assays were sufficiently controlled and standardized.”
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020, methodology): “The searches identified 4,897 abstracts, and ultimately, 87 papers met the selection criteria.(11,14-99) Articles were selected for inclusion in the systematic review of the evidence based on the following criteria:”
- Machine learning applications in cancer prognosis and prediction (2014, methodology): “In the DREAM project [68], several attempts to combine clinical treatment scores with signatures based on immunohistochemistry [69] as well as expression-based signatures such as PAM50 [70] and Oncotype DX [71] reveal the extensive work done for improving treatment based on the incorporation of diff”